Transcept Pharmaceuticals, Inc. to Report First Quarter 2013 Financial Results and Host Conference Call on May 8, 2013

Published: May 02, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Point Richmond, Calif., May 1, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Wednesday, May 8, 2013, at 4:30 p.m. Eastern Time to discuss its first quarter 2013 financial results. The conference call will follow the release of the Transcept first quarter 2013 financial results after the close of market that day.

Conference Call Information




Date: Wednesday, May 8, 2013


Time: 4:30 p.m. ET


Dial-in (U.S.): (877) 638-4558


Dial-in (International): (914) 495-8537

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call and will be available through June 30, 2013.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.

Contact:
Transcept Pharmaceuticals, Inc.
Leone Patterson
Vice President and Chief Financial Officer
(510) 215-3512
lpatterson@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news